Anti-DLL3 Antibody (FZ-A038)

FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of the DLL3 targeting ADC (antibody drug conjugate) FZ-AD005 (BPS Bioscience #84250). DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine). The application of ADCs (antibody drug conjugates) is also been evaluated. FZ-AD005, an ADC targeting DLL3, is composed of the antibody FZ-A038 and a topoisomerase I inhibitor has shown potent antitumor activity in preclinical models of SCLC.